OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.28 -0.02 (-5.33%) As of 08/4/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About CytoDyn Stock (OTCMKTS:CYDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytoDyn alerts:Sign Up Key Stats Today's Range$0.27▼$0.3050-Day Range$0.26▼$0.3652-Week Range$0.10▼$0.49Volume1.47 million shsAverage Volume1.24 million shsMarket Capitalization$347.34 millionP/E Ratio27.73Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Read More CytoDyn Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreCYDY MarketRank™: CytoDyn scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CytoDyn. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CytoDyn is 27.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.10.Price to Earnings Ratio vs. SectorThe P/E ratio of CytoDyn is 27.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.18.Read more about CytoDyn's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.02% of the outstanding shares of CytoDyn have been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in CytoDyn has recently increased by 3.76%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoDyn does not currently pay a dividend.Dividend GrowthCytoDyn does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.02% of the outstanding shares of CytoDyn have been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in CytoDyn has recently increased by 3.76%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News SentimentN/A Search Interest1 people have searched for CYDY on MarketBeat in the last 30 days. MarketBeat Follows6 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoDyn insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of CytoDyn is held by insiders.Percentage Held by InstitutionsOnly 5.06% of the stock of CytoDyn is held by institutions.Read more about CytoDyn's insider trading history. Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Stock News HeadlinesCytoDyn Inc. (CYDY) Latest Stock News & Headlines - Yahoo FinanceJuly 1, 2025 | ca.finance.yahoo.comCytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with LeronlimabJuly 1, 2025 | globenewswire.comA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal CancerJune 24, 2025 | globenewswire.comCytoDyn Announces New Data Suggesting Novel Mechanism Of Action Of Leronlimab In Solid TumorsMay 15, 2025 | nasdaq.comCytoDyn Releases ESMO Breast Cancer Meeting PosterMay 15, 2025 | globenewswire.comCytoDyn's new data shows leronlimab could treat solid tumorsMay 13, 2025 | msn.comCytoDyn highlights potential of lead drug against solid tumors with new dataMay 13, 2025 | seekingalpha.comSee More Headlines CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.1097 at the beginning of 2025. Since then, CYDY stock has increased by 152.5% and is now trading at $0.2770. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) posted its quarterly earnings results on Friday, July, 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings7/25/2025Today8/05/2025Next Earnings (Estimated)8/13/2025Fiscal Year End5/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio27.73 Forward P/E RatioN/A P/E GrowthN/ANet Income$3.74 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-4.40% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-3.46Miscellaneous Outstanding Shares1,253,930,000Free Float1,247,160,000Market Cap$347.34 million OptionableNot Optionable Beta1.23 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:CYDY) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.